GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Abstract 6652: Employing ex vivo 3D-Screen technology for the development of rational combinations of immuno-oncology drugs in tumor organoids of fresh patient tissue
    American Association for Cancer Research (AACR) ; 2020
    In:  Cancer Research Vol. 80, No. 16_Supplement ( 2020-08-15), p. 6652-6652
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 80, No. 16_Supplement ( 2020-08-15), p. 6652-6652
    Abstract: Introduction: Modern evaluation of novel immuno-oncological drug combinations requires a multi-faceted approach to accurately determine immune-cell activation and tumor cell viability. Additionally, retention of the intact tumor microenvironment through preparation of 3D tumor organoids is essential for the quantification of any drug-mediated changes to the complex cell-to-cell interactions that may result in changes in tumor cell viability and the immune cell profile. Here, we use multiplex cytokine analysis in combination with high-content confocal imaging of tumor cell killing to detail the efficacy of rational drug combinations for the treatment of 3D tumor organoids produced from fresh patient tumor tissue. Materials and Methods: All patient tumor samples were obtained with patient consent and under IRB approval. Generation of 3D tumor organoids (150µm) from fresh patient tumor tissue such as bladder, colotrectal and kidney tumors was accomplished using proprietary techniques. Tumor organoids were pooled to represent tumor heterogeneity in treatment groups including nivolumab (anti-PD1), urelumab (anti-4-1BB) and a cGAS-STING agonist singly and in differing combinations. Following incubation, culture media was collected for multiplex analysis of cytokine production, and quantitative analysis of tumor cell killing was determined with high content confocal imaging. Results: Here we demonstrated the efficacy of the 3D-Screen technology for the evaluation of the therapeutic efficacy of different immuno-oncology drugs alone and in combinations. High content confocal imaging analysis of the 3D tumor organoid microenvironment allowed for detection of changes for tumor cell killing in response to varying treatment conditions. Additionally, altered pro-and anti-inflammatory cytokine production correlated with observations of tumor cell viability. Furthermore, we correlated tumor response to ex vivo treatments with clinical, histo-morphological and molecular characteristics of the tumors in an attempt to identify markers associated with drug responsiveness. Conclusion: These data show that 3D-Screen methodology is an effective tool for the rapid assessment of novel immuno-oncological drug combinations using fresh patient 3D tumor organoids. Furthermore, this technology would prove useful in clinical applications for the determination of specific therapeutic regimens for individualized patient care. Citation Format: Vijayendra Agrawal, Mibel M. Pabón, Jared C. Ehrhart, Tina Pastoor, Jenny M. Kreahling, Soner Altiok. Employing ex vivo 3D-Screen technology for the development of rational combinations of immuno-oncology drugs in tumor organoids of fresh patient tissue [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 6652.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/1538-7445.AM2020-6652
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2020
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Abstract 935: Optimization of checkpoint inhibitor-TKI combinations in renal cell carcinoma using an ex vivo 3D tumor organoid model of fresh patient tissue with intact TME
    American Association for Cancer Research (AACR) ; 2020
    In:  Cancer Research Vol. 80, No. 16_Supplement ( 2020-08-15), p. 935-935
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 80, No. 16_Supplement ( 2020-08-15), p. 935-935
    Abstract: Introduction: Renal Cell Carcinoma (RCC) is highly resistant to systemic chemotherapy. Different tyrosine kinase inhibitors (TKIs), such as sunitinib, sorafenib and axitinib have been introduced in the treatment of RCC with improved outcomes in the subsets of RCC patients. Tumor microenvironment (TME) plays a critical role in response to TKIs as well as to immuno-oncology drugs including the PD1 inhibitor nivolumab. Given the heterogeneity of the TME in each patient's tumor, optimization of combination treatments is highly desirable. Here, we employed an ex vivo 3D-tumor organoid model with unaltered TME to identify the most effective TKI-nivolumab combinations in individual RCC tumors and further explored the impact on both tumor cell viability and immune cell activation. Materials and Methods: All RCC tumor samples were obtained with patient consent and relevant IRB approval. For the ex vivo assays 3D organoids measuring 150 micron in size were treated with sunitinib, sorafenib, axitinib alone or in combination with nivolumab ex vivo. Treatment-mediated changes in tumor immune cell composition including CD4 and CD8 T-cells, Tregs, NK cells, macrophages, cell surface expression of checkpoint proteins as well as T-cell activation were evaluated by multiplex flow cytometry. Multiplex cytokine assays were performed to assess drug-induced changes in cytokine release. High content confocal analysis was used to quantify tumor cell killing. Results: We showed that TKI and nivolumab treatments alone had limited immune cell activation and tumor cell killing efficacy in RCC while their combination showed significant variations in T-cell activation by flow cytometry analysis and tumor cell killing by high content confocal imaging among different patient samples. We correlated tumor response to ex vivo treatments with tumor characteristics and further characterized the impact of treatment on TME in each tumor sample in an attempt to identify markers associated with drug responsiveness. Conclusion: In this comprehensive study we used a physiologically relevant 3D tumor organoid model to demonstrate the impact of the heterogeneity of TME on TKI/nivolumab treatments in renal cell carcinoma. This approach can be used to identify the most effective drug and drug combinations in RCC and may improve personalized immunotherapy for individual patients in clinical studies. Citation Format: Jared C. Ehrhart, Mibel M. Pabón, Vijayendra Agrawal, Tina Pastoor, Jenny M. Kreahling, Soner Altiok. Optimization of checkpoint inhibitor-TKI combinations in renal cell carcinoma using an ex vivo 3D tumor organoid model of fresh patient tissue with intact TME [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 935.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/1538-7445.AM2020-935
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2020
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Abstract 1501: Employing 3D-ACT platform to assess the ability of stromal-targeting agents to improve penetration and efficacy of cell therapy
    American Association for Cancer Research (AACR) ; 2021
    In:  Cancer Research Vol. 81, No. 13_Supplement ( 2021-07-01), p. 1501-1501
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 81, No. 13_Supplement ( 2021-07-01), p. 1501-1501
    Abstract: Background: Adoptive T cell therapy (ACT) has demonstrated great clinical success for the treatment of hematological malignancies. However, the unique challenges presented by solid tumors has significantly limited their utility. The primary characteristic of an effective ACT is the ability to selective identify tumor cells. In case of solid tumors, the ACT faces the additional hurdle requiring penetration into the tumor microenvironment (TME) while retaining function. Tumors develop highly immunosuppressive stroma which serves as a mechanical hinderance for the penetration and function of activated effector cells. In this study we used our 3D-ACT platform to investigate the ability of focal adhesion kinase (FAK) inhibitors to enhance the penetration of engineered cells into the intact patient tumor stroma and their efficacy within the tumor immune microenvironment. Methods: All tumor samples were obtained with patient consent and relevant IRB approval. Unpropagated 3D tumoroids with intact TME measuring 150 µm in size were prepared from fresh tumor samples of renal cell carcinoma (RCC), and colorectal carcinoma (CRC) using proprietary technology developed at Nilogen Oncosystems. Engineered T cells were labeled with different cell tracker fluorescent dyes to monitor cell movements and locations within tumoroids by confocal analysis. 3D tumoroids were treated with vehicle only or FAK inhibitors and exposed to CAR-T cells at 10:1 E:T ratio. Cell penetration within tumoroids and tumor cell killing was measured by high-content confocal imaging combined with 3D-image analysis. ACT cell activation was monitored using multiparameter flow cytometry analysis and multiplex cytokine release assays to assess changes in the TME. Results: Our studies demonstrated that the confocal-based high-content real time imaging platform, combined with custom image analysis algorithms, allowed for monitoring of treatment-mediated tumor cell killing with structural analysis of engineered T-cells in the intact 3D tumoroids. Our data revealed that CAR-T cell penetration into tumoroids greatly varied between different tumor types and was heavily influenced by the tumor's stromal components. Treatment with FAK-inhibitors led to alterations within the TME, which subsequently impacted penetration and efficacy of CAR-T cells as assessed by flow cytometry and confocal imaging. Conclusion: The ex vivo model described here (3D-ACT) retains the TME and replicate the heterogeneity of tumor stroma to provide provides a clinically relevant platform to evaluate the influence of the tumor stromal components on engineered T cell functions. We believe the 3D-ACT platform can effectively be used to screen for drugs that can promote ACT penetration into the tumor stroma and survival within the tumor microenvironment. Citation Format: Zhisong Tong, Stephen Iwanowycz, Jared Ehrhart, Mibel M. Pabón, Tina Pastoor, Soner Altiok. Employing 3D-ACT platform to assess the ability of stromal-targeting agents to improve penetration and efficacy of cell therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1501.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/1538-7445.AM2021-1501
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2021
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Advances In the Cell-Based Treatment of Neonatal Hypoxic–Ischemic Brain Injury
    Informa UK Limited ; 2013
    In:  Future Neurology Vol. 8, No. 2 ( 2013-03-31), p. 193-203
    Details
    In: Future Neurology, Informa UK Limited, Vol. 8, No. 2 ( 2013-03-31), p. 193-203
    Type of Medium: Online Resource
    ISSN: 1479-6708 , 1748-6971
    URL: Article
    DOI: 10.2217/fnl.12.85
    Language: English
    Publisher: Informa UK Limited
    Publication Date: 2013
    detail.hit.zdb_id: 2254603-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Abstract 1566: Monitoring the impact of IL15 in combination with Sting agonists and nivolumab on activation and proliferation of tumor resident immune cells in 3D-EX platform of intact patient tumoroids
    American Association for Cancer Research (AACR) ; 2021
    In:  Cancer Research Vol. 81, No. 13_Supplement ( 2021-07-01), p. 1566-1566
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 81, No. 13_Supplement ( 2021-07-01), p. 1566-1566
    Abstract: Background: The major goal of many immune-oncology (IO) therapeutics is improving the functionality of cytotoxic T cells through inhibiting checkpoints or through targeting stimulatory pathways. Tumor infiltrating myeloid cells are often educated within the tumor microenvironment (TME) to adopt regulatory phenotypes and become a major barrier to effective immune responses. Generation of an optimal immune response likely requires a combination of agents designed to promote anti-tumor T cell activation and to recondition the TME to support T cell functions. We generated patient derived 3D-tumoroids which retain the tumors stroma and suppressive immune landscape. This platform allowed for the screening of immune agonists targeting the IL15, Sting, or 41BB pathways alone or in combination with checkpoint inhibitors to identify the most effective combination in fresh patient tumoroid samples ex vivo. Methods: 3D-tumoroids approximately 150 µm in size were generated from fresh patient tumor samples which were obtained with informed consent and relevant IRB approval. Tumoroids were treated ex vivo with an IL15 agonist or Sting pathway agonists alone or in combination with nivolumab. Multi-parameter flow cytometry was used to analyze treatment-mediated changes inCD4/CD8 and NK cell activation. Additionally, we directly measured proliferation of T-cells, Tregs and myeloid cell populations in response to ex vivo treatments through EDU incorporation assay by flowcytometry. Immune cell function was further assessed by multiplex cytokine analysis and treatment-induced tumor cell killing was determined by high content confocal imaging. Results: Our data showed that IL15 treatment alone and select Sting agonists in combination and nivolumab had significant impact on activation and proliferation of tumor resident T-cells in their intact TME. Additionally, by using the 3D-EX platform, somewhat unexpectedly, we also observed meaningful changes in Tregs and multiple tumor infiltrating myeloid subsets including macrophages and dendritic cells upon ex vivo treatment with the IO drugs used in this study. Enhancement in pro-inflammatory cytokines production and immune cell functional phenotype were further correlated with tumor cell killing ex vivo. Conclusion: Our data reveals the power of the 3D-EX platform to identify combinations of immunotherapy agents capable of overcoming the unique suppressive environment developed by an individual tumor. Furthermore, the 3D-EX platform provides unique insight into the microenvironment to better identify compensatory mechanisms limiting the efficacy of IO therapeutics that may help to develop rational combination strategies. We believe the 3D-EX platform is clinically relevant and capable of significantly accelerating immuno-oncology drug discovery. Citation Format: Mibel M. Pabón, Jared Ehrhart, Stephen Iwanowycz, Zhisong Tong, Tina Pastoor, Soner Altiok. Monitoring the impact of IL15 in combination with Sting agonists and nivolumab on activation and proliferation of tumor resident immune cells in 3D-EX platform of intact patient tumoroids [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1566.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/1538-7445.AM2021-1566
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2021
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Brain Region‐Specific Histopathological Effects of Varying Trajectories of Controlled Cortical Impact Injury Model of Traumatic Brain Injury
    Wiley ; 2016
    In:  CNS Neuroscience & Therapeutics Vol. 22, No. 3 ( 2016-03), p. 200-211
    Details
    In: CNS Neuroscience & Therapeutics, Wiley, Vol. 22, No. 3 ( 2016-03), p. 200-211
    Abstract: Traumatic brain injury ( TBI ) occurs when the head is impacted by an external force causing either a closed or penetrating head injury through a direct or accelerating impact. In laboratory research, most of the TBI animal models focus on a specific region to cause brain injury, but traumatic injuries in patients do not always impact the same brain regions. The aim of this study was to examine the histopathological effects of different angles of mechanical injury by manipulating the trajectory of the controlled cortical impact injury ( CCI ) model in adult Sprague‐Dawley rats. Methods The CCI model was manipulated as follows: conventional targeting of the frontal cortex, farthest right angle targeting the frontal cortex, closest right angle targeting the frontal cortex, olfactory bulb injury, and cerebellar injury. Three days after TBI , brains were harvested to analyze cortical and hippocampal cell loss, neuroinflammatory response, and neurogenesis via immunohistochemistry. Results Results revealed cell death in the M1 region of the cortex across all groups, and in the CA 3 area from olfactory bulb injury group. This observed cell death involved upregulation of inflammation as evidenced by rampant MHCII overexpression in cortex, but largely spared Ki‐67/nestin neurogenesis in the hippocampus during this acute phase of TBI . Conclusion These results indicate a trajectory‐dependent injury characterized by exacerbation of inflammation and different levels of impaired cell proliferation and neurogenesis. Such multiple brain areas showing varying levels of cell death after region‐specific CCI model may closely mimic the clinical manifestations of TBI .
    Type of Medium: Online Resource
    ISSN: 1755-5930 , 1755-5949
    URL: Issue
    URL: Article
    DOI: 10.1111/cns.2016.22.issue-3
    DOI: 10.1111/cns.12485
    Language: English
    Publisher: Wiley
    Publication Date: 2016
    detail.hit.zdb_id: 2423467-9
    detail.hit.zdb_id: 2423461-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Peripheral injection of human umbilical cord blood stimulates neurogenesis in the aged rat brain
    Springer Science and Business Media LLC ; 2008
    In:  BMC Neuroscience Vol. 9, No. 1 ( 2008-12)
    Details
    In: BMC Neuroscience, Springer Science and Business Media LLC, Vol. 9, No. 1 ( 2008-12)
    Abstract: Neurogenesis continues to occur throughout life but dramatically decreases with increasing age. This decrease is mostly related to a decline in proliferative activity as a result of an impoverishment of the microenvironment of the aged brain, including a reduction in trophic factors and increased inflammation. Results We determined that human umbilical cord blood mononuclear cells (UCBMC) given peripherally, by an intravenous injection, could rejuvenate the proliferative activity of the aged neural stem/progenitor cells. This increase in proliferation lasted for at least 15 days after the delivery of the UCBMC. Along with the increase in proliferation following UCBMC treatment, an increase in neurogenesis was also found in the aged animals. The increase in neurogenesis as a result of UCBMC treatment seemed to be due to a decrease in inflammation, as a decrease in the number of activated microglia was found and this decrease correlated with the increase in neurogenesis. Conclusion The results demonstrate that a single intravenous injection of UCBMC in aged rats can significantly improve the microenvironment of the aged hippocampus and rejuvenate the aged neural stem/progenitor cells. Our results raise the possibility of a peripherally administered cell therapy as an effective approach to improve the microenvironment of the aged brain.
    Type of Medium: Online Resource
    ISSN: 1471-2202
    URL: Article
    DOI: 10.1186/1471-2202-9-22
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2008
    detail.hit.zdb_id: 2041344-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Gender‐Linked Stem Cell Alterations in Stroke and Postpartum Depression
    Wiley ; 2015
    In:  CNS Neuroscience & Therapeutics Vol. 21, No. 4 ( 2015-04), p. 348-356
    Details
    In: CNS Neuroscience & Therapeutics, Wiley, Vol. 21, No. 4 ( 2015-04), p. 348-356
    Abstract: Stroke is a significant unmet clinical need. The current stroke treatment of tissue plasminogen activator is limited to the very acute 4.5 h after disease onset which benefits only less than 3% of ischemic stroke patients. Our overarching hypothesis advances the notion that gender, which has been established as a comorbidity factor of stroke, plays a key role in regenerative medicine, in particular stem cell therapy. We hypothesize that gender is a key factor in culture‐induced stemness of adult stem cells. Our goal is to provide new evidence supporting gender effects on stroke and stem cells for the purpose of enhancing our understanding of the pathophysiology of the disease and developing novel stem cell‐based therapeutics targeting gender‐relevant stress hormones as manifested in a stroke‐postpartum depression paradigm.
    Type of Medium: Online Resource
    ISSN: 1755-5930 , 1755-5949
    URL: Issue
    URL: Article
    DOI: 10.1111/cns.2015.21.issue-4
    DOI: 10.1111/cns.12339
    Language: English
    Publisher: Wiley
    Publication Date: 2015
    detail.hit.zdb_id: 2423467-9
    detail.hit.zdb_id: 2423461-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    The Battle of the Sexes for Stroke Therapy: Female- Versus Male-Derived Stem Cells
    Bentham Science Publishers Ltd. ; 2013
    In:  CNS & Neurological Disorders - Drug Targets Vol. 12, No. 3 ( 2013-05-01), p. 405-412
    Details
    In: CNS & Neurological Disorders - Drug Targets, Bentham Science Publishers Ltd., Vol. 12, No. 3 ( 2013-05-01), p. 405-412
    Type of Medium: Online Resource
    ISSN: 1871-5273
    URL: Article
    DOI: 10.2174/1871527311312030013
    Language: English
    Publisher: Bentham Science Publishers Ltd.
    Publication Date: 2013
    detail.hit.zdb_id: 2228394-8
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    Abstract 2649: An ex vivo 3D tumoroid model of fresh patient tissue (3D-EX) to assess the efficacy of anti-angiogenic compounds in renal cell carcinoma
    American Association for Cancer Research (AACR) ; 2021
    In:  Cancer Research Vol. 81, No. 13_Supplement ( 2021-07-01), p. 2649-2649
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 81, No. 13_Supplement ( 2021-07-01), p. 2649-2649
    Abstract: Introduction: Renal Cell Carcinoma (RCC) is highly resistant to systemic chemotherapy; however, targeting pro-angiogenic pathways has shown significant clinical benefit. The development of targeted anti-angiogenetic agents has been hampered by the lack of clinically relevant models for screening. We have previously reported that the generation of 3D-tumoroids containing the unaltered tumor stroma could effectively be used to detect tumor response to small molecule inhibitors as well as antibody-based therapeutic agents. In this study we described a novel ex vivo platform to develop anti-angiogenic therapeutic strategies using fresh patient tumoroids of hepatocellular carcinoma and renal cell carcinoma. Materials and Methods: All fresh tumor samples were obtained with patient consent and relevant IRB approval. For the ex vivo assays, 3D tumoroids measuring 150 µm in size were treated with tyrosine kinase inhibitors (TKIs) sunitinib, sorafenib or axitinib. Treatment-mediated changes in endothelial cell viability was assessed by the confocal-based high-content real time imaging platform using fluorescent labeled anti-CD31 and anti-VEGFR2 antibodies, combined with custom image analysis algorithms. Additionally, treatment-mediated changes in tumor immune cell composition including CD4 and CD8 T-cells, Tregs, NK cells, macrophages, cell surface expression of checkpoint proteins as well as T-cell activation were evaluated by multiplex flow cytometry. Results: Our data shows that endothelial cells and capillary structures could clearly be visualized within3D tumoroids by confocal microscopy. Furthermore, we were able to quantify apoptotic cell death in endothelial cells induced by TKI inhibitors. Flow cytometry analysis demonstrated significant changes in T-cell activation upon treatment with TKIs that closely correlated with increased proinflammatory cytokine release. Observations found that the combination of anti-angiogenic treatments and immuno-modulatory agents significantly improved treatment responses. Conclusion: The ex vivo platform described in this study allowed assessment of the effect of anti-angiogenetic TKIs on tumor capillary endothelial cells as well as on tumor resident immune cell populations in intact RCC tumoroids of fresh patient tumor samples. We believe this clinically relevant approach can be used to identify the most effective anti-angiogenic and immunotherapeutic drugs and drug combinations in RCC and may improve personalized therapy for individual patients in clinical studies. Citation Format: Jared Ehrhart, Mibel M. Pabón, Stephen Iwanowycz, Zhisong Tong, Tina Pastoor, Soner Altiok. An ex vivo 3D tumoroid model of fresh patient tissue (3D-EX) to assess the efficacy of anti-angiogenic compounds in renal cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2649.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/1538-7445.AM2021-2649
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2021
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...